RNA Leaders reposted this
Delivery Approaches for RNA Therapeutics RNA Leaders Brad Niles Steven F. Dowdy, Ph.D. Zdravka Medarova Christopher Hart David Katzmann
RNA Leaders is a high-quality therapeutic conference, focusing on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids & RNA targets. For investors and pharma, it offers the chance to peruse the science and meet biotechs working on a variety of different product types within an emerging space. For biotechs, it offers the chance to learn how others are meeting field-wide challenges like regulation and delivery and hear about the work being done beyond their immediate space. Join us in San Diego for RNA Leaders USA - 4-5 September 2024 or in Basel for RNA Leaders Europe Congress - 5 - 6 March 2025. You’ll hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies and source the partners who are helping to deliver drugs to patients. RNA Leaders USA 🇺🇸 - https://www.lsxleaders.com/rna-leaders-usa-congress RNA Leaders Europe 🇨🇭 - https://www.lsxleaders.com/rna-leaders-world-congress
External link for RNA Leaders
RNA Leaders reposted this
Delivery Approaches for RNA Therapeutics RNA Leaders Brad Niles Steven F. Dowdy, Ph.D. Zdravka Medarova Christopher Hart David Katzmann
RNA Leaders reposted this
Associate Director | Drug Discovery & Development | Biologics | Gene Therapies | Business | Strategy | ex-Janssen | ex-Moderna | ex-Applied BioMath
We are at the RNA Leaders, USA Congress, San Diego, Sep 4-5. It’s a pleasure to reconnect with friends and industry leaders, reminding me of my time at Moderna during its early stages when I had the opportunity to model Lipid Nanoparticles containing RNA, using Coarse-Grained MD simulations—a first in the industry. I’m excited to explore the latest roadmaps, opportunities, and challenges in our field. At Certara, we are committed to enhancing #efficiency for our clients, which is especially crucial in today’s environment, where every company, from small #startups to large #pharma, is focused on #optimizing their processes. Let's connect and discuss how we can help you! We can support you with: - Translational research: pre-IND - Guiding FIH dose selection - Selection and application of biomarkers - Predicting immunogenicity - Addressing the needs of special populations (i.e. pediatric and geriatrics) - Optimizing trial design through virtual patients - Precision dosing using virtual twins - According to the IQ Consortium of leading pharmaceutical companies: QSP/Model Informed Drug Development can: --Accelerate regulatory approval by as much as 2 years --Reduce cost of drug development by $30-70M
#RNALeaders USA Congress has officially kicked off this morning in San Diego! We’re thrilled to welcome 350+ attendees, ready to explore the cutting-edge developments in the evolving RNA landscape. Stay tuned for exciting updates as we dive into two days of insightful discussions, networking, and innovation! #RNA #Biotech #mRNA
🧬RNA Leaders Industry Update🧬 ⭐ Exciting to see Bayer and NextRNA Therapeutics have entered a $547M collaboration to accelerate the development of small molecules targeting lncRNAs in oncology 🔗 https://lnkd.in/dS2kfpTk 🔬 A team of researchers lead by Yu Zhao, Harbin Medical University, have demonstrated a polymer-locking fusogenic liposome to transport siRNA and CRISPR-Cas9 complexes across the blood-brain barrier and into glioblastoma cells. 🔗 https://lnkd.in/dHBeH5jM ⭐ Researchers at the University of San Diego lead by Prashant Mali highlight two new methods for producing circRNA, using ubiquitously expressed RtcB protein, and bacterial enzyme. 🔗 https://lnkd.in/d_b-JiY4 Come and join us next week in San Diego this September for RNA Leaders USA, where top industry leaders will share exciting updates!... 🎤 Samir Ounzain, HAYA Therapeutics - Discussing technology to identify new lncRNA targets in the dark genome 🎤 James McArthur, PepGen - Exploring the use of peptide-conjugated oligos to target neuromuscular disorders 🎤 Rabia T. K., Serna Bio - Sharing insights on RNA architecture and using ML to explore small molecule interactions 🔶 Confirm your place in San Diego here: https://lnkd.in/ewCpitZg #RNALeaders #lncRNA #darkgenome #RNAdelivery #siRNA #CRISPR
🧬RNA Leaders Industry Update🧬 ⭐ Versant Ventures and Novartis have launched Borealis Biosciences, Inc., a next generation RNA therapeutics company targeting kidney disease, with funding of $150M. 🔗https://lnkd.in/dbhUkksD ⭐ Exciting to see Abogen, Inc. have announced development of Cis-System -based circRNAs. 🔗 https://lnkd.in/eyvgQSp6 ⭐ BioNTech SE and Pfizer receive US FDA approval for Omicron KP.2-adapted COVID-19 Vaccine in individuals aged 6 months+. 🔗 https://lnkd.in/eM6mPGmD ⭐ Researchers at University of Rochester Medical Center and Indivumed Therapeutics have discovered a new way to classify distinct types of colon cancer based on RNA splicing events. 🔗 https://lnkd.in/ef4uweBf Come and join us in San Diego this September for RNA Leaders USA, where top industry leaders will share exciting updates!... 🎤 Raj Reddy, Canary Cure - Sharing insights into a novel RNA therapeutic approach to treating obesity 🎤 Rabia T. K., Serna Bio - Exploring the functional transcriptome 🎤 David Katzmann, Arrowhead Pharmaceuticals - Discussing the importance of receptor-ligand pairing for siRNA delivery 🔶 See the full 2024 agenda here: https://lnkd.in/eaHkSBNu #RNALeaders #mRNA #siRNA #nextgenRNA
🧬RNA Leaders Industry Update🧬 ⭐ EnPlusOne Biosciences and the Wyss Institute at Harvard University have entered collaboration with up to $27M agreement by Advanced Research Projects Agency for Health (ARPA-H), to progress a disease agnostic immunotherapeutic RNA platform with the potential to provide rapidly deployable treatment for cancer and infectious diseases. 🔗https://lnkd.in/g4VaBViy ⭐ Nuntius Therapeutics and Taiho Pharmaceutical Co., Ltd., announce partnership to advance cell-specific delivery of next-gen mRNA therapeutics. 🔗https://lnkd.in/gid9fah3 🔬 Denali Therapeutics announce publication of pre-clinical data in Science Translational Medicine highlighting the use of their oligonucleotide transfer vehicle platform to accomplish ASO delivery to the CNS and muscle following IV administration. 🔗 https://lnkd.in/edHCCNkg ⭐ Avidity Biosciences, Inc. announce proposed public offering of their common stock, with proceedings to be used for advancement of antibody oligonucleotide conjugate (AOC) clinical programs. 🔗 https://lnkd.in/e47uGAf2 Join us in San Diego this September for RNA Leaders USA, where top industry leaders will share more exciting updates! Hear from... 🎤 Gene Yeo, UC San Diego – Delving into RBP biology and RBP-RNA interactions 🎤 Daniel Fischer, Tevard Biosciences – Discussing the use of tRNA therapeutics to tackle genetic diseases 🎤 Brad Niles, ARIZ Precision Medicine – Exploring the design and delivery of PRDM2 siRNA for cancer 🔶 Secure your place this September here: https://lnkd.in/ewCpitZg #RNALeaders #RNAdelivery #ASO #siRNA #tRNA #RNAtherapeutics
📣 New Episode Alert: RNA Leaders Podcast Series! Dive into the latest RNA Leaders Podcast where Arcturus Therapeutics' Chief Strategy Officer, Roberta Duncan, MBA shares groundbreaking insights on mRNA technology and the future of therapeutics. Discover how their cutting-edge advancements with self-amplifying RNA could reshape healthcare as we know it. From innovative treatments to the challenges of the biotech industry, this episode is a must-listen for anyone passionate about the future of RNA. 📅 Plus, get a sneak peek into what Roberta will be discussing at the RNA Leaders event in less than three weeks in San Diego. Our final early bird is expiring tomorrow, so make sure you secure your part in the critical conversation happening in RNA. 👉 https://lnkd.in/dDBQQQVh 🔗 Listen now: https://lnkd.in/dsMefyJY #RNALeaders #Biotech #Pharma #HealthcareInnovation #Podcast #RNA #RNALeaders24 #healthcare #mRNA #therapeutics
🧬RNA Leaders Industry Update🧬 🔬 Fantastic to see Mass General Brigham's work on a phase 1 study of a neoantigen therapy at the investigational level. The individualized therapy is with encoded mRNA has shown that a patient’s immune system can target cancer cells. 🔗 https://lnkd.in/eqyzmGB6 🔬 Exciting to see University of Toronto researchers using CRISPR to manipulate and control RNA splicing precisely 🔗 https://lnkd.in/evre7Xp7 ⭐ Congratulations to Karius has obtaining a BARDA contract to develop RNA-based pathogens 🔗 https://lnkd.in/ekMhetC5 ⭐Great teamwork from the USP - Universidade de São Paulo on developing urinary mRNA-based biomarkers for non invasive bladder cancer 🔗 https://lnkd.in/ePFVSPfV Join us this September 4-5 for RNA Leaders USA, where top industry leaders will share more exciting updates!... 🎤 Tony Walshe, Alnylam Pharmaceuticals- Discussing the potential of siRNA for CNS targets. 🎤 Carter Palmer, Third Element Bio - Delving into a novel approach of RNA therapeutics to selectively control neuroinflammation 🎤 张巍怡, RiboX Therapeutics - Sharing insights on developing circular RNA as transformative medicine. 🔶 Confirm your place in San Diego here!: https://lnkd.in/dhTfJ4VB
🧬RNA Leaders Industry Update🧬 🔬 Exciting to see Myeloid Therapeutics has initiated patient dosing of its second clinical in vivo mRNA CAR program, MT-303, against advanced hepatocellular carcinoma. 🔗 https://lnkd.in/endr_kFe ⭐ Congratulations to AIRNA who have raised a further $60M, taking their series A round to $90M. The proceeds will be used to progress AIRNA's lead RNA editing candidate for the treatment of alpha-1 antitrypsin deficiency into the clinic. 🔗 https://lnkd.in/dyFacVDZ 🔬 Fantastic to see BioNTech SE have announced positive topline phase 2 results for its mRNA immunotherapy candidate BNT11, in combination with Regeneron's anti-PD-1 monoclonal antibody cemipilimab in patients with advanced melanoma. 🔗 https://lnkd.in/ecxWAdZQ ⭐ SINERGIUM Biotech supported by World Health Organization & Medicines Patent Pool, launch a new initative to accelerate mRNA vaccine candidate development against human avian influenza (H5N1) for manufactures in low- and middle-income countries. 🔗 https://lnkd.in/ddZkPb76) Join us this September 4-5 for RNA Leaders USA, where top industry leaders will share more exciting updates!... 🎤 Karin Jooss, Gritstone bio - Discussing the potential of saRNA to target advanced metastatic solid tumours. 🎤 Todd Chappell, Korro Bio, Inc. - Delving into a novel ADAR editing platform, OPERA (Oligonucleotide Promoted Editing of RNA) to treat liver and CNS disease. 🎤 Rachel Groppo, Johnson & Johnson - Sharing insights on accelerating discovery of saRNA vaccines and therapeutics. 🔶 Confirm your place in San Diego here!: https://lnkd.in/ewCpitZg #RNALeaders #RNAediting #ADAR #mRNAimmunotherapy
🎉 Happy World RNA Day from #RNALeaders! 🎉 Today, we're celebrating the incredible advancements in #RNA technology, from groundbreaking therapeutics to life-saving vaccines and beyond. Join us at our next event this September in San Diego to continue the celebration and exploration of RNA innovations. #RNAday Find out more here: https://lnkd.in/e3v_CJp5